Research programme: p38 MAP kinase inhibitors - Ambit Biosciences
Alternative Names: p38 MAP kinase inhibitors research programme - Ambit Biosciences; p38-alpha mitogen-activated protein kinase inhibitors - Ambit BiosciencesLatest Information Update: 20 Apr 2006
At a glance
- Originator Ambit Biosciences Corporation
- Class
- Mechanism of Action P38 mitogen-activated protein kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 20 Apr 2006 No development reported - Preclinical for Inflammation in USA (unspecified route)
- 24 Feb 2004 Ambit Biosciences' p38 MAP kinase inhibitors programme is available for partnering (http://www.ambitbio.com)
- 24 Feb 2004 Preclinical trials in Inflammation in USA (unspecified route)